AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company with operations in the USA and China, closed a $37m Series A financing round.
The round was led by existing investor, InnoPinnacle Fund, with participation from new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.
The proceeds from the financing will further support the clinical development of AHB-137, AusperBio’s lead product candidate. Additionally, the funds will advance its proprietary Med-Oligo™ technology platform and its product pipelines.
Led by Dr. Guofeng Cheng, co-founder and CEO, AusperBio is a clinical-stage biopharmaceutical company dedicated to advancing targeted oligonucleotide therapies, with the goal of achieving functional cure for chronic hepatitis B (CHB) infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
AHB-137, a novel unconjugated antisense oligonucleotide (ASO) developed within AusperBio’s proprietary Med-Oligo™ ASO technology platform, was designed to treat chronic hepatitis B for a functional cure. Its compelling preclinical and Phase 1 clinical data was highlighted at the 2023 EASL™ conference and the 2024 EASL™ conference, respectively. This novel dual-mechanism ASO is presently undergoing a Phase 1b trial across multiple international study sites and a concurrent Phase 2 trial in China. Through a global development strategy, AHB-137 is advancing rapidly towards the goal of HBV cure.
FinSMEs
15/07/2024